Illumina Unveils its Most Accurate and Comprehensive Secondary Analysis Platform, Boosting Lab Capabilities

DRAGEN™ v4.0 brings greater accuracy, comprehensiveness, and efficiency to genomic analysis than ever before, unlocking the full potential of genomics to improve human health SAN DIEGO, July 27, 2022 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and…

Click here to view original post